Synonym
Nicomol; Cholexamin; Cholexamine; K 31; K-31; K31;
IUPAC/Chemical Name
2,2,6,6-Tetrakis(nicotinoyloxymethyl)cyclohexanol
InChi Key
VRAHPESAMYMDQI-UHFFFAOYSA-N
InChi Code
InChI=1S/C34H32N4O9/c39-28(24-6-1-12-35-16-24)44-20-33(21-45-29(40)25-7-2-13-36-17-25)10-5-11-34(32(33)43,22-46-30(41)26-8-3-14-37-18-26)23-47-31(42)27-9-4-15-38-19-27/h1-4,6-9,12-19,32,43H,5,10-11,20-23H2
SMILES Code
OC1C(COC(C2=CN=CC=C2)=O)(COC(C3=CN=CC=C3)=O)CCCC1(COC(C4=CN=CC=C4)=O)COC(C5=CN=CC=C5)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
Nicomol is a niacin derivative with antilipidemic activity.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
640.65
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
TBD
1: Shimoda K, Akiba T, Matsushima T, Rai T, Abe K, Hoshino M. [Niceritrol decreases serum phosphate levels in chronic hemodialysis patients]. Nihon Jinzo Gakkai Shi. 1998 Jan;40(1):1-7. Japanese. PMID: 9513376.
2: Shinozawa S, Gomita Y, Araki Y. Protective effects of various drugs on adriamycin (doxorubicin)-induced toxicity and microsomal lipid peroxidation in mice and rats. Biol Pharm Bull. 1993 Nov;16(11):1114-7. doi: 10.1248/bpb.16.1114. PMID: 8312867.
3: Yasui M, Ota K, Oshima A. Effects of ibudilast on calcium deposition in soft tissues of rabbits with atherosclerosis. J Int Med Res. 1990 Sep- Oct;18(5):415-24. doi: 10.1177/030006059001800510. PMID: 2257963.
4: Yoshikuni Y, Chokai S, Ozaki T, Yoshida H, Nakane M, Kuwabara K. Hypolipidemic effect of NS-1 and other related drugs in rhesus monkeys. Atherosclerosis. 1988 Nov;74(1-2):149-56. doi: 10.1016/0021-9150(88)90201-8. PMID: 3214474.
5: Shinozawa S, Gomita Y, Araki Y. Protection against adriamycin (doxorubicin)-induced toxicity in mice by several clinically used drugs. Acta Med Okayama. 1987 Feb;41(1):11-7. doi: 10.18926/AMO/31766. PMID: 2436440.
6: Watanabe T, Manna H, Suga T. Effects of some hypolipidemic drugs on biochemical values and on hepatic peroxisomal enzymes of normolipemic rat. J Pharmacobiodyn. 1981 Oct;4(10):743-50. doi: 10.1248/bpb1978.4.743. PMID: 6798192.
7: Ikeda S, Nagashima H, Taketa K, Watanabe M. Effect of nicomol on high density lipoprotein (HDL) subfractions, HDL2e and HDL3e, separated by electrophoresis. Acta Med Okayama. 1981 Apr;35(2):143-8. doi: 10.18926/AMO/31266. PMID: 6456646.
8: Watanabe M, Taketa K, Nagashima H, Yamamoto Y. Effect of nicomol on HDL cholesterol level. Acta Med Okayama. 1979 Aug;33(4):323-6. PMID: 227232.
9: Yamazaki N, Suzuki Y, Kamikawa T, Ogawa K, Mizutani K, Kakizawa N, Yamamoto M. Arrhythmogenic effects of acute free fatty acid mobilization on ischemic heart. Recent Adv Stud Cardiac Struct Metab. 1976 May 26-29;12:271-7. PMID: 201997.
